Introduction: In the last few years, significant advances in molecular biology have provided
new therapeutic options for colorectal cancer (CRC). The development of new drugs that …

Human colorectal cancer (CRC) is the third most commonly diagnosed malignancies and
the prognosis for patients with recurrent or metastatic disease is extremely poor. Although …

Following dramatic success in many types of advanced solid tumors, interest in
immunotherapy for the treatment of colorectal cancer (CRC) is increasingly growing. Given …

There are increasing incidences and mortality rates for colorectal cancer in the world. It is
common for chemotherapy and radiation given to patients with colorectal cancer to cause …

Introduction: Colorectal cancer (CRC) is the fourth most common cancer and the second
leading cause of cancer-related death worldwide. Surgery, chemotherapy, radiation therapy …

Colorectal cancer (CRC) is among the most prevalent and deadly neoplasms worldwide.
According to GLOBOCAN predictions, its incidence will increase from 1.15 million CRC …

Immunotherapy is the latest revolution in cancer therapy. It continues to show impressive
results in malignancies like melanoma and others. At least so far, effects are modest in …

As one of the main threats to human life (the fourth most dangerous and prevalent cancer),
colorectal cancer affects many people yearly, decreases patients' quality of life, and causes …

Modulation of the interaction between the immune system and the tumor microenvironment
has long been a target of cancer research, including colorectal cancer (CRC). Approaches …

Colorectal cancer (CRC) represents the third cause of cancer‐related mortalities worldwide.
The progression of CRC to the metastatic phase significantly compromises the overall …